How do SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors compare in reducing cardiorenal outcomes in patients with type 2 diabetes?
SGLT-2 inhibitors and GLP-1 receptor agonists are superior to DPP-4 inhibitors for cardiorenal outcomes in type 2 diabetes, with SGLT-2 inhibitors showing greater benefit for heart failure and renal events.
SGLT-2 inhibitors and GLP-1RA are superior to DPP-4 inhibitors in reducing the risk of most cardiorenal outcomes; SGLT-2 inhibitors are superior to GLP-1RA in reducing the risk of HHF and renal events; GLP-1RA only reduced the risk of nonfatal stroke. Both SGLT-2 inhibitors and GLP-1RA should be the preferred treatment for type 2 diabetes and cardiorenal diseases.
Giugliano et al. (Wed,) studied this question.